Bristol-Myers Squibb Collaboration (Details)		3 Months Ended
	Jan. 07, 2022 USD ($) item Program $ / shares shares	Mar. 31, 2023 USD ($) $ / shares	Mar. 31, 2022 USD ($)	Dec. 31, 2022 $ / shares
Common stock, par value | $ / shares		$ 0.0001		$ 0.0001
Aggregate purchase price		$ 448,000	$ 65,000
Total transaction price		$ 123,187,000
Collaboration Agreement
Number of collaboration programs | Program	2
Additional number of collaboration programs | Program	2
Upfront cash payment receivable	$ 100,000,000
Milestone payments receivable upon achievement of certain development and regulatory milestones	235,000,000
Sales-based milestone payments	$ 500,000,000
Termination of Royalty term	12 years
Common stock issued | shares	2,160,760
Common stock, par value | $ / shares	$ 23.14
Aggregate purchase price	$ 50,000,000
Common stock, premium per share | $ / shares	$ 7.82
Premium amount of common stock	$ 23,200,000
Aggregate purchase price excluding premium	$ 26,800,000
Number of Commitments | item	4
FCDI Collaboration Agreement | Collaboration Agreement
Upfront cash payment receivable	$ 10,000,000